Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Biocon and Mylan Launch Trastuzumab Biosimilar, Ogivri™ (trastuzumab-dkst), in the U.S.

Posted On: 2019-12-02 23:52:47

This FDA-approved product, co-developed by Biocon Biologics and Mylan, was unanimously recommended by the FDA Oncologic Drugs Advisory Committee

Mylan to offer Ogivri in both the 420mg and 150mg strengths, increasing access to treatment for thousands of HER2-positive breast and gastric cancer patients

Biocon Ltd. (BSE code: 532523, NSE: BIOCON) and Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin® (trastuzumab). Ogivri is available in a 420mg multi-dose vial and a 150mg single-dose vial in order to provide patient dosing and treatment flexibility.

Ogivri was the first biosimilar trastuzumab approved by the U.S. Food and Drug Administration (FDA) and unanimously recommended by the FDA Oncologic Drugs Advisory Committee (ODAC). Ogivri is approved for all indications of Herceptin including for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma). Trastuzumab and biosimilar trastuzumab products contain a Boxed Warning for cardiomyopathy, infusion reactions, pulmonary toxicity and embryo-fetal toxicity.

Two supplemental Biologics License Applications were recently approved by the FDA, expanding the manufacturing capability for Ogivri, as well as Mylan and Biocon's first U.S. biosimilar, Fulphila®, a biosimilar to Neulasta®. Mylan and Biocon Biologics have sufficient manufacturing capacity to fulfil demand in the U.S. and global markets for both products.

Dr Christiane Hamacher, CEO, Biocon Biologics, said: "The U.S. launch of Ogivri, the biosimilar trastuzumab co-developed by Biocon Biologics and Mylan, marks a significant milestone in our biosimilars journey. It is an important endorsement of our science, development and manufacturing capabilities in the area of monoclonal antibodies. The introduction of both 420mg multi-use vials and 150mg single-use vials of a high quality biosimilar trastuzumab with robust long-term efficacy and safety data will offer greater choice and value to patients, prescribers and payors in the U.S. As a global frontrunner in biosimilars, Biocon Biologics is committed to fulfil unmet patient needs by providing greater affordability for enhanced patient access. We aspire to serve 5 million patients through our biosimilars portfolio and cross a revenue milestone of US$ 1bn by FY22.

"Ogivri is the second biosimilar from our partnered portfolio being commercialized by Mylan in the U.S. Last year, through the launch of Fulphila we helped in expanding patient access to biosimilar Pegfilgrastim," she added.

Mylan President Rajiv Malik commented: "As one of the largest suppliers of oncology medicines in the U.S., we are proud to offer Ogivri, biosimilar trastuzumab, in both the 420mg and 150mg strengths and help increase more affordable access to this important treatment option for breast and gastric cancer patients. With regulatory approval for our biosimilar trastuzumab in more than 80 countries worldwide, we are bringing vast global biosimilars experience to the U.S. and look forward to continuing our work with all stakeholders in the healthcare system to reduce costs, improve access and advance care. With Ogivri, Fulphila and our generic oncology portfolio, Mylan is uniquely positioned to provide a broad range of treatment options for oncology patients."

Malik continued, "Today's launch has been achieved through years of hard work, as a result of our successful collaboration with Biocon. Our early settlement and license with Roche to bring this product to market allows us to launch Ogivri without legal risk."

FDA approval of Ogivri was based on robust data demonstrating that Ogivri is highly similar to Herceptin and no clinically meaningful differences exist between the biosimilar product and Herceptin in terms of safety, purity and potency. Long-term results of the landmark HERITAGE study including overall survival data at 36 months were presented at this year's American Society of Clinical Oncology (ASCO) Annual Meeting.

Dr. Hope S. Rugo, professor of medicine at the University of California, San Francisco, and lead author of the HERITAGE study commented: "Trastuzumab-dkst (Ogivri) has many firsts to its credit. It was one of the first biosimilar oncology products to get a unanimous approval vote at an ODAC meeting, and it was the first biosimilar study to be published in the Journal of the American Medical Association. In this context, the HERITAGE study had a unique trial design that not only evaluated objective response rate at week 24 as its primary endpoint but also assessed key endpoints including progression-free survival rate and overall survival at 36 months. The concordant efficacy data across all three endpoints conclusively demonstrated that Ogivri was similar to Herceptin, and patients without progression now continue on Ogivri as maintenance therapy. We are pleased that patients with HER2-positive cancers now have an additional treatment option backed by robust safety and efficacy data, including long-term 36-month data. The worldwide introduction of this agent has already improved access to trastuzumab."

Ogivri is the second biosimilar to be offered by Mylan through the Mylan-Biocon Biologics partnership in the U.S. and the second FDA-approved biosimilar through this collaboration to support cancer patients. A full suite of patient services for Ogivri will be offered through the Mylan Advocate program. Mylan and Biocon launched the world's first biosimilar trastuzumab in India in 2014.

Today, Mylan has one of the largest and most diverse biosimilars portfolios, with 20 biosimilar and insulin analog products in development or on the market.

Shares of BIOCON LTD. was last trading in BSE at Rs.285.95 as compared to the previous close of Rs. 281.65. The total number of shares traded during the day was 399358 in over 6254 trades.

The stock hit an intraday high of Rs. 291.9 and intraday low of 281.95. The net turnover during the day was Rs. 114772369.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Givaudan Partners with TCS to Transform its Global Data Center Operations

TCS Study Finds 78% of UK Companies Plan to Digitally Transform their Business Model Within 3 years

Qatar Investment Authority to invest INR 3,200 Crore in Adani Electricity Mumbai Limited

Mold-Tek Technologies Ltd enters into MOU with Italian and Indian Engineering Services Companies

KNR Constructions receives orders worth of Rs. 240.60 Crores from Greater Hyderabad Municipal Corporation

Infosys Awarded UN Global Climate Action Award in 'Carbon Neutral Now' Category at COP 25

TCS iON to Empower Kerala Youth with Future-ready Job Skills

City Union Bank Ltd opens new branches at Mylavaram and Mathikere

Future Supply Chain and Nippon Express Strategic Partnership aspires to be India's Leading Logistics Player

Hindustan Aeronautics Ltd signs MOU for wage revision

QGO Finance Ltd to issue 1,000 NCDs

Infosys Recognized as a 2020 'Top Employer' in Australia, Singapore and Japan

CRISIL reaffirms ratings on the bank facilities of Excel Industries Limited

JSPL commissioned its 4th Coke Oven Battery at Angul Steel Plant

L&T Technology Services Ltd launches Project Neelachala - a CSR Program for those affected by cyclone Fani

Airtel launches 'Airtel Wi-Fi Calling' - India's first Voice over Wi-Fi service

Everest Group recognizes L&T Technology Services as 'Leader' in Automotive Engineering Services

Announcing General Availability of Version 11 of Majesco Distribution Management Platform

ADNOC and Reliance Industries Limited Sign Agreement to Explore Development of Ethylene Dichloride Facility in Ruwais

CCI approves acquisition of stake in Future Supply Chain Solutions Limited by Nippon Express

Ethos Ltd opens two new stores at World Trade Park, Jaipur

Tasty Dairy Specialities Ltd enters into agreement with Noluma International

IDBI Bank to dilute stake in IDBI Capital Market Securities Ltd and IDBI Intech Ltd

Kimia Biosciences Ltd granted 'Site Certificate Under WHO-GMP Certification Scheme'

YES Bank board to reconvene on Dec 10, 2019 to continue discussion on investment proposals

Ministry of Technology and Communications, Oman and Wipro ink MoU to launch Open Source CoE

BEML launches new hydraulic excavator

Bharti Infratel Ltd board declares 2nd interim dividend of Rs. 2.75

Tata Motors Group global wholesales at 89,671 in November 2019

Ramco Systems in association with NelsonHall launches Digital Payroll Maturity Assessment Tool

Panacea Biotec announces launch of ViLACT for treatment of Uncontrolled Type 2 Diabetes Mellitus patients

STL to collaborate with IIT Madras for 5G advancements in India

Shashijit Infraprojects Ltd receives order from Vapi Nagar Palika

SC Soft, an Aurionpro Group Company, steps into Africa and Central America: Mexico with Automatic Fare collection projects

Subex and RAG announce first of its kind alliance to leverage Blockchain for combatting fraud

L&T Technology Services Ltd appoints Ms. Apurva Purohit as an Independent Director

Quick Heal Technologies Limited recognised by NASSCOM's DSCI as an industry pioneer in the Indian cybersecurity space

Chief Digital Officer Role Having Powerful Impact on Digital Transformation: Mindtree Survey

Aditya Birla Fashion and Retail Ltd appoints additional director, vice-chairman

Redington arm increases stake in Rajprotim Supply Chain Solutions Ltd to 100%

Grant Thornton releases interim physical survey report on more than 3,000 Nextgen Vakrangee Kendra

Dilip Buildcon Ltd receives order from Delhi Metro

Hero MotoCorp to increase prices of its products from Jan 1, 2020

HDFC Bank Ltd board to consider Q3 results on Jan 18, 2020

CRISIL downgrades PC Jeweller Ltd's ratings to default grade

Bharat Gears Ltd announces employee strike at its Lonand Unit

INSILCO Ltd updates on renewal of its applications with UPPCB and CGWA

CRISIL A2+ rating assigned to Newgen Software Technologies' short-term facilities

City Union Bank opens 3 new branches on Dec 9, 2019

AXIS Bank reappoints S Vishvanathan as independent director







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019